In November 2020, Springtide announced a Series A financing of $18.1 million. Springtide is an an interdisciplinary multi-site practice treating children with autism spectrum disorder. The Company’s in-center care experience provides a coordinated, tech-enabled wrap-around for families who want their children to get all of their care in one setting.
In October 2020, Olema Pharmaceuticals announced a Series C Preferred stock financing of $85 million. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast and gynecologic cancers.